KBC Group
CDTX

KBC Group’s Cidara Therapeutics CDTX Stock Holding History

KBC Group’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-376
Closed -$83K – 1858
2025
Q4 		$83K Buy
+376
New +$60.8K ﹤0.01% 1401

KBC Group's CDTX Position: Q1 2026 in Review

KBC Group sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 376 shares — an estimated $83K sold.

KBC Group first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $83K in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

  • KBC Group reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • KBC Group sold 376 Cidara Therapeutics shares in Q1 2026, an estimated $83K.
  • KBC Group first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
  • KBC Group's Cidara Therapeutics position peaked at $83K in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.